A small, early-stage trial of a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd showed that nearly fifty  percent of the patients were alive without their cancer worsening 18 months after they were diagnoised. Please click here to read the full story at Reuters.